The aim of the study is to evaluate early safety, clinical efficacy and long-term outcomes of mitral allografts and stented biological prosthesis in tricuspid valve replacement for primary tricuspid valve diseases.
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Mortality
Timeframe: 30-day period after surgery
Stroke
Timeframe: 30-day period after surgery
Severe valve dysfunction
Timeframe: 1-year after surgery, annually, assessed up to 3 years
Freedom from prosthetic endocarditis
Timeframe: 1-year after surgery, annually, assessed up to 3 years
Freedom from reoperation
Timeframe: 1-year after surgery, annually, assessed up to 3 years
New pacemaker implantation
Timeframe: 1-year after surgery, annually, assessed up to 3 years